Anxiety and Depression Treatment Market: Current Analysis and Forecast (2021-2027)

Anxiety and Depression Treatment Market: Current Analysis and Forecast (2021-2027)

The global anxiety and depression treatment market is anticipated to grow with an elevated CAGR of around 3% over the forecast period (2021-2027). Anxiety and Depression are the most common mental disorders where the melancholy mood lasts for a long duration. Thus, affects the overall efficiency of the person, and depression is directly linked with stress and anxiety. The long term anxiety is considered one of the symptoms of depression.

The rapidly developing novel drugs and rising awareness about the severity of mental disorders among people contribute to the significant market growth of the anxiety and depression treatment market. The changing lifestyle preferences such as consumption of the substance and problems like insomnia are the major factors contributing to the increasing number of depression cases. Moreover, the increasing unemployment around the globe is also responsible for the increasing stress and anxiety levels among the youths resulting in the increasing demand for better treatment of anxiety and depression. As per the international labor organization, the global unemployment rate is increasing by 6.7% annually.

GlaxoSmithKline plc, Pfizer, Inc., Eli Lilly and Company, H. Lundbeck A/S, Forest Laboratories, Inc., AstraZeneca, Merck & Company, Inc., Johnson & Johnson, and Sanofi-Aventis are some of the prominent players operating in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with new varieties of anxiety and depression treatments.

Insights Presented in the Report
"Amongst Drug Type, anti-depressant drug segment holds the major share”

Based on drug types, the anxiety and depression treatment market is segmented into antidepressants, anticonvulsants, atypical antipsychotics, benzodiazepines, and Beta-blockers. The anti-depressant drug class is expected to have significant growth during the forecast period owing to the continuous development and approval of the new medications for the treatment of anxiety and depression. For instance, in April 2022, Lupin Ltd received approval from the US health regulator to market its generic version of Desvenlafaxine extended-release tablets used for treating depression.
"Amongst distribution channels, online channel segment holds the major share”

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online channels. Amongst them, the online pharmacies distribution channel is expected to witness significant growth due to the rising investment in e-pharmacy across the world. However, anxiety and depression drugs are mostly available only through prescription. Thus, doctors are now preferring e-prescriptions to allow patients to get easy access to medicine with the help of e-prescriptions. Countries, like the United Kingdom, are putting more effort into the implementation of e-prescriptions. For instance, the electronic prescription service (EPS) will be rolled out across England after a trial run in 60 GP practices and hundreds of pharmacies, in 2019. National Health Service (NHS) aimed to save USD 373 million in the next two years.

Amongst disorder types, the major depressive disorder segment holds the major share”

Based on the disorder type, the market is segmented into major depressive disorder (MDD), OCD, phobia, PTSD, and others. Among them, the market for major depressive disorder is expected to witness significant growth. The growth of the segmented is mainly attributed to the increasing level of workplace stress and the number of suffering people along with a lack of the appropriate knowledge about the severity of the diseases leads to the development of stress into major depressive disorder. According to the American workplace and NIOSH Reports, 80% of workers feel stress on the job among them 40% of workers reported their job was very or extremely stressful.
"North America represents one of the largest markets of Anxiety and Depression Treatment market”

For a better understanding of the market dynamics of the Anxiety and Depression Treatment market, a detailed analysis was conducted for different regions across the globe including North America (U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. In 2020, North America accounted for the majority share in the market. The increasing number of awareness programs by the governments is driving the market for anxiety and depression disorders in the region. Canada, for instance, launched the mental illness awareness week in October 2021 to educate people about mental health and its effects.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts
• The report presents a quick review of overall industry performance at one glance
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
• The study comprehensively covers the market across different segments
• Deep dive regional level analysis of the industry